ArticlePloS one2022
Implementation of a COVID-19 Genomic Surveillance Regional Network for Latin America and Caribbean region.
Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 32 citations in OpenAlex.
- Genomic epidemiology of SARS-CoV-2 in Peru from 2020 to 2024.Communications medicine · 2026Article
- Genomic, socio-environmental, and sequencing capability patterns in the surveillance of SARS-CoV-2 in Latin America and the Caribbean up to 2023.Scientific reports · 2025Article
- From Epidemics to Pandemics: Over a Decade of Strengthening SARInet Laboratory Surveillance and Response for Respiratory Viruses in the Americas.The Journal of infectious diseases · 2025Article
- Genomic surveillance of SARS-CoV-2 in the Andean Community (2020-2024): integrating regional sequencing efforts from Colombia, Ecuador, Peru, and Bolivia through "ORAS-CONHU" program.Frontiers in public health · 2025Article
- Singapore's COVID-19 Genomic Surveillance Programme: Strategies and Insights From a Pandemic Year.Influenza and other respiratory viruses · 2024Article
- Strategies to Enhance Diagnostic Capabilities for the New Drug-Resistant Tuberculosis (DR-TB) Drugs.Pathogens (Basel, Switzerland) · 2024Review
- Updated Surveillance Metrics and History of the COVID-19 Pandemic (2020-2023) in Latin America and the Caribbean: Longitudinal Trend Analysis.JMIR public health and surveillance · 2024Article
- Dispersion patterns of SARS-CoV-2 variants Gamma, Lambda and Mu in Latin America and the Caribbean.Nature communications · 2024Article
- Discovery of novel genetic syndromes in Latin America: Opportunities and challenges.Genetics and molecular biology · 2024Article
- Genomic surveillance of SARS-CoV-2 reveals highest severity and mortality of delta over other variants: evidence from Cameroon.Scientific reports · 2023Article
- Effectiveness of COVID-19 vaccines against hospitalisation in Latin America during three pandemic waves, 2021-2022: a test-negative case-control design.Lancet regional health. Americas · 2023Article
- First sequenced cases of Omicron BA.2 sublineage in Ecuador.Virus research · 2023Article
- Enhancing SARS-CoV-2 Surveillance through Regular Genomic Sequencing in Spain: The RELECOV Network.International journal of molecular sciences · 2023Article
- Infectious diseases genomic surveillance capacity in the Caribbean: A retrospective analysis of SARS-CoV-2.Lancet regional health. Americas · 2023Article
- SARS-CoV-2 diagnostic testing rates determine the sensitivity of genomic surveillance programs.Nature genetics · 2023Article
- Implementing molecular tuberculosis diagnostic methods in limited-resource and high-burden countries.Breathe (Sheffield, England) · 2022Review
- SARS-CoV-2 diagnostic testing rates determine the sensitivity of genomic surveillance programs.medRxiv : the preprint server for health sciences · 2022Article
- Detection of SARS-CoV-2 infection in thyroid follicular cells from a COVID-19 autopsy series.European thyroid journal · 2022Article
- SARS-CoV-2 Variants in Rhode Island; May 2022 Update.Rhode Island medical journal (2013) · 2022Article
- Genomic surveillance of SARS-CoV-2 in Puerto Rico enabled early detection and tracking of variants.Communications medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The timely release of SARS-CoV-2 first genomic sequences allowed the identification of the etiologic agent and development of diagnostic protocols. Genomic sequencing was a crucial step in generating data for driving laboratory response and detections of SARS-CoV-2 since the start of the COVID-19 pandemic. Because of all the progression and achievements that timely release of genetic sequence data represents in the public health response, the Pan American Health Organization (PAHO) in collaboration with countries' public health laboratories, started implementation of a network for strengthening the Latin America and Caribbean (LAC) region on timely generation of SARS-CoV-2 genomic data. Here we describe the implementation of the COVID-19 Genomic Surveillance Regional Network in the Americas region during the beginning of the pandemic. The establishment of this network has strengthened laboratory response capacity at the country level, as well as facilitated timely release of SARS-CoV-2 genomic information to be used to complement the multiple response strategies for COVID-19 pandemic mitigation. As genomic epidemiology is useful for guiding public health decisions on outbreak and response, we also analysed the first SARS-CoV-2 genomic sequence data from countries of the Latin America and Caribbean Region.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.